Antiplatelet Therapy in Secondary Prevention After Myocardial Infarction

Definition and pathophysiological basis

Secondary prevention after myocardial infarction (MI) encompasses long-term interventions intended to reduce recurrent infarction, ischaemic stroke, cardiovascular death, and progression of atherosclerotic disease in patients with established coronary or other atherosclerotic vascular disease. Antiplatelet therapy is a central component because platelet activation and aggregation contribute importantly to arterial thrombus formation, recurrent coronary occlusion, and stent thrombosis.

Aspirin inhibits the cyclooxygenase-1 pathway, whereas P2Y12 receptor antagonists inhibit a separate platelet-activation pathway. The principal oral P2Y12 inhibitors discussed in the source material are clopidogrel, prasugrel, and ticagrelor. Combining aspirin with a P2Y12 inhibitor produces dual antiplatelet therapy (DAPT), while treatment with one antiplatelet drug constitutes single antiplatelet therapy (SAPT).

The benefit of antiplatelet therapy must always be balanced against bleeding. This balance changes according to the clinical setting, time from MI or percutaneous coronary intervention (PCI), ischaemic risk, bleeding risk, need for anticoagulation, and whether coronary stents are present.

Clinical objectives of therapy

The main objectives of antiplatelet treatment after MI are to:

• prevent recurrent MI;

• reduce ischaemic stroke and cardiovascular mortality;

• prevent stent thrombosis after PCI;

• reduce recurrent atherothrombotic events in chronic coronary disease;

• preserve the benefit of coronary intervention while limiting major and clinically relevant bleeding.

Long-term antiplatelet therapy after STEMI is associated with approximately a 25% reduction in recurrent infarction, stroke, or cardiovascular death. In the cited evidence, this corresponded to 36 fewer events per 1000 treated patients.

Aspirin for long-term secondary prevention

Standard role

Aspirin remains the traditional antiplatelet agent for long-term secondary prevention in patients with established coronary disease, including those with or without previous MI. It is generally continued indefinitely unless contraindications, intolerance, clinically important bleeding, or a competing anticoagulation strategy alters the treatment plan.

The usual maintenance dose is:

• Aspirin 75–100 mg once daily after ACS or STEMI.

• Aspirin 75–162 mg once daily is described as an acceptable secondary-prevention range in chronic coronary disease.

For prolonged treatment, doses of 75–100 mg daily appear to provide similar efficacy to higher doses while reducing bleeding risk. Low-dose aspirin is also preferred in patients with intracoronary stents.

In acute ACS, aspirin should be administered as soon as possible in the absence of contraindications, using a loading dose followed by maintenance treatment. The source material does not specify the loading dose.

Efficacy and harms

In secondary-prevention trials involving patients with previous vascular disease, aspirin reduced the combined incidence of non-fatal MI, non-fatal ischaemic stroke, and vascular death from 8.2% to 6.7% per year. The relative reductions were approximately 31% for non-fatal MI, 22% for non-fatal ischaemic stroke, and 9% for vascular death.

Aspirin increased major gastrointestinal and extracranial bleeding, although the overall reduction in ischaemic events outweighed the increase in serious bleeding in the populations studied. There was no evidence of a different aspirin effect according to sex.

P2Y12 inhibitor monotherapy

A P2Y12 inhibitor may be used instead of aspirin for long-term secondary prevention, particularly when aspirin is contraindicated, not tolerated, or when an individualized post-PCI strategy favours P2Y12 inhibitor monotherapy.

Clopidogrel

Clopidogrel 75 mg once daily is an established alternative to aspirin. In patients with previous MI, stroke, or peripheral arterial disease, clopidogrel produced a modest reduction in ischaemic events compared with aspirin 325 mg daily. The evidence overall supports clopidogrel monotherapy as an effective and safe alternative for long-term secondary prevention in chronic coronary disease.

Clopidogrel is particularly relevant in the following circumstances:

• aspirin hypersensitivity or intolerance;

• selected post-PCI de-escalation strategies;

• patients requiring anticoagulation in whom clopidogrel is preferred if an antiplatelet agent must be combined with oral anticoagulation;

• situations in which prasugrel or ticagrelor are contraindicated, unavailable, or considered unsuitable because of bleeding risk or older age.

Clopidogrel produces less potent and more variable platelet inhibition than prasugrel or ticagrelor. Carriers of a CYP2C19 loss-of-function allele have less platelet inhibition and a higher risk of ischaemic events after PCI than non-carriers. Nevertheless, routine genotype or platelet-function testing is not supported for patients with chronic coronary disease. In a patient undergoing high-risk PCI who is known to carry a CYP2C19 loss-of-function allele, replacing aspirin plus clopidogrel with aspirin plus ticagrelor or prasugrel is considered reasonable.

Ticagrelor

Ticagrelor provides more potent and less variable platelet inhibition than clopidogrel, but has greater bleeding potential. Its role as monotherapy is less firmly established than that of aspirin or clopidogrel.

In selected patients with chronic coronary disease or stabilized post-ACS disease after PCI, ticagrelor monotherapy may be considered, particularly when ischaemic risk is high and bleeding risk is not high. The evidence remains less robust than for aspirin or clopidogrel, and the optimal timing and duration are uncertain. The only ticagrelor monotherapy dose specifically tested in the cited evidence was 90 mg twice daily.

In selected patients with previous MI, ticagrelor can also be added to aspirin as extended intensified therapy. For patients one to three years after MI with at least one high-risk feature—age over 65 years, diabetes mellitus, a second MI, multivessel coronary disease, or chronic kidney disease—ticagrelor reduced ischaemic events but increased major, non-fatal bleeding. The 60 mg twice-daily dose was safer and better tolerated than 90 mg twice daily and is the approved dose for this extended strategy in the source material.

Ticagrelor plus aspirin in patients with diabetes and established chronic coronary disease but no previous MI or stroke produced a modest reduction in ischaemic events but substantially increased major bleeding, including intracranial haemorrhage. Accordingly, this strategy requires careful selection.

Prasugrel

Prasugrel is a potent oral P2Y12 inhibitor used principally as part of DAPT in ACS patients undergoing PCI. It is preferred over clopidogrel when appropriate and, in the cited guideline strategy for ACS patients proceeding to PCI, may be preferred to ticagrelor.

Prasugrel should not be used routinely as long-term monotherapy in chronic coronary disease because the available evidence is limited to a single-arm study with only three months of follow-up.

Dual antiplatelet therapy after MI

STEMI

Patients who survive the initial STEMI course remain at substantial risk of recurrent events. In the absence of high bleeding risk or bleeding complications, DAPT with aspirin plus a P2Y12 inhibitor is recommended for 12 months after STEMI.

The preferred P2Y12 agents in patients undergoing PCI are prasugrel or ticagrelor. Clopidogrel is an alternative when either potent agent is unavailable, contraindicated, or not tolerated.

Evidence cited for STEMI patients undergoing PCI indicates:

• prasugrel reduced the composite of cardiovascular death, MI, or stroke compared with clopidogrel at both 30 days and 15 months;

• prasugrel also reduced definite or probable stent thrombosis;

• ticagrelor showed a similar direction of benefit, with reductions in the composite of cardiovascular death, recurrent MI, or stroke, definite or probable stent thrombosis, and all-cause mortality compared with clopidogrel.

The optimal timing of P2Y12 inhibitor administration before PCI remains uncertain. Pretreatment with clopidogrel reduced 30-day cardiovascular death or MI in analyses incorporating STEMI and non-ST-elevation ACS populations. Prehospital ticagrelor administration did not improve coronary reperfusion but reduced stent thrombosis without additional bleeding compared with in-hospital administration in the cited STEMI study.

Cangrelor is an intravenous, potent, rapidly acting and reversible P2Y12 inhibitor that can be used during PCI when a patient has not received a P2Y12 inhibitor before the procedure. In the cited evidence, it reduced death, MI, revascularization, or stent thrombosis compared with clopidogrel in patients undergoing PCI, including primary PCI for STEMI.

Chronic coronary disease after MI

In chronic coronary disease after MI, indefinite SAPT with aspirin is generally recommended when there is no indication for oral anticoagulation. Clopidogrel is the principal alternative.

DAPT beyond the initial post-MI period should not be routine for every patient. It may be considered when ischaemic risk is high and bleeding risk is acceptable. Options include:

• continued aspirin plus clopidogrel or prasugrel after PCI;

• aspirin plus ticagrelor 60 mg twice daily in selected patients one to three years after MI;

• aspirin plus rivaroxaban 2.5 mg twice daily in selected patients with stable atherosclerotic disease.

All intensified strategies increase bleeding, and treatment should be reassessed regularly.

DAPT after PCI

Elective PCI for chronic coronary disease

After PCI for chronic coronary disease, aspirin plus clopidogrel is recommended to reduce stent thrombosis and MI compared with aspirin alone. Ticagrelor should not routinely replace clopidogrel for elective PCI because it did not significantly reduce PCI-related MI or major myocardial injury and increased minor bleeding in the cited trial.

The default DAPT duration after PCI for chronic coronary disease is six months.

Shorter treatment may be appropriate in selected patients:

• DAPT for one to three months may be beneficial when bleeding risk is high;

• in patients without high bleeding risk, shortening DAPT should generally be reserved for those without high ischaemic risk;

• after one month of uneventful DAPT, discontinuation in high-bleeding-risk patients was non-inferior to continued standard therapy for ischaemic events and reduced major or clinically relevant non-major bleeding.

High bleeding risk

High bleeding risk is identified by the presence of one major or two minor Academic Research Consortium for High Bleeding Risk criteria. Multiple major criteria are associated with progressively increasing bleeding risk.

For chronic coronary disease patients with high bleeding risk, discontinuation of DAPT one to three months after PCI is recommended in the cited guideline material. Decisions should remain individualized because both the procedural and clinical ischaemic risk influence the safety of abbreviated treatment.

High ischaemic risk without high bleeding risk

Patients with high ischaemic risk and no high bleeding risk may be candidates for intensified or prolonged antithrombotic therapy. Potential strategies include:

• prolonged DAPT with aspirin plus clopidogrel or prasugrel;

• aspirin plus ticagrelor 60 mg twice daily after prior MI;

• aspirin plus rivaroxaban 2.5 mg twice daily in stable atherosclerotic disease.

The choice should reflect the patient’s clinical characteristics and the eligibility criteria of the supporting evidence. Treatment beyond the durations studied in randomized trials lacks randomized evidence, and both bleeding and ischaemic risk should be reviewed periodically.

Extended intensified antithrombotic therapy

Aspirin plus ticagrelor

In patients with MI one to three years previously who also have at least one high-risk characteristic, ticagrelor 60 mg twice daily added to aspirin reduced ischaemic events over three years but increased TIMI major bleeding. The 60 mg twice-daily regimen was better tolerated and associated with less bleeding than 90 mg twice daily.

This approach is most appropriate when the anticipated reduction in recurrent thrombosis outweighs the bleeding hazard. The cited evidence suggests greater relative benefit among patients with diabetes, multivessel coronary disease, or peripheral arterial disease.

Aspirin plus rivaroxaban

In stable atherosclerotic disease, aspirin plus rivaroxaban 2.5 mg twice daily reduced ischaemic events compared with aspirin alone but increased modified-ISTH major bleeding. There was no significant difference in intracranial or fatal bleeding, and death rates were lower with the combination.

Rivaroxaban 5 mg twice daily as monotherapy did not reduce ischaemic events compared with aspirin in the cited evidence. The low-dose combination should therefore not be confused with full-dose anticoagulation or rivaroxaban monotherapy.

Patients with diabetes, peripheral arterial disease, mild chronic kidney disease, or active smoking appeared to derive greater benefit from aspirin plus rivaroxaban than those without these features.

Prolonged DAPT

An additional 18 months of DAPT after one year post-PCI reduced ischaemic events compared with aspirin alone, but increased moderate and severe bleeding; all-cause mortality also tended to be higher. The balance of benefit and harm was more favourable in patients whose PCI followed ACS than in those undergoing elective PCI for chronic coronary disease.

Antiplatelet therapy and oral anticoagulation

The combination of antiplatelet therapy and oral anticoagulation requires particular caution because bleeding increases substantially with combination treatment. Adding a single antiplatelet agent to an oral anticoagulant increases major bleeding by more than 50%, while triple therapy with an oral anticoagulant, aspirin, and clopidogrel more than doubles bleeding.

Stable coronary disease with an indication for anticoagulation

In patients with atrial fibrillation and stable coronary disease more than one year after revascularization, oral anticoagulant monotherapy produced lower rates of bleeding, ischaemic events, and mortality than oral anticoagulation combined with a single antiplatelet agent in the cited evidence.

Accordingly, in patients with a relatively low coronary ischaemic risk, particularly those without recent MI or recent stenting, antiplatelet therapy may be omitted when full-dose oral anticoagulation is indicated.

Recent ACS or coronary stenting

When atrial fibrillation coexists with recent ACS or coronary stenting, the risks and benefits of oral anticoagulation must be reassessed because combination therapy increases bleeding. If triple therapy is unavoidable, the cited recommendations are to:

• keep triple therapy as brief as possible;

• use the lower end of the therapeutic INR range when warfarin is used;

• avoid prasugrel and ticagrelor in combination with oral anticoagulation;

• prefer clopidogrel as the P2Y12 inhibitor;

• routinely use a proton-pump inhibitor to reduce gastrointestinal bleeding;

• consider withdrawal of aspirin from triple therapy when clinically appropriate.

After PCI, direct oral anticoagulant-based strategies are generally supported by the cited evidence, with lower ischaemic event rates despite shortening the period of aspirin exposure.

Perioperative interruption

Premature interruption of DAPT after recent coronary stent implantation is the strongest predictor of stent thrombosis. The preferred strategy is to delay elective non-cardiac surgery until completion of the intended DAPT course:

• six months after elective PCI;

• 12 months after ACS.

For time-sensitive surgery, at least one month of DAPT should generally have been completed after modern drug-eluting stent implantation. In high-risk cardiovascular patients, such as those with ACS, at least three months should be considered before time-sensitive surgery.

Once the P2Y12 inhibitor has been discontinued, surgery should generally proceed while aspirin is continued. For patients receiving long-term DAPT for additional indications, P2Y12 inhibitors may need to be withheld for three to seven days depending on the specific drug. Management of P2Y12 inhibitor monotherapy requires interdisciplinary assessment of operative bleeding and ischaemic risk; possible approaches include continuing monotherapy, switching to aspirin, briefly interrupting treatment, or bridging, although the supporting evidence is limited.

Practical selection of therapy

Guideline-based principles

The cited guideline recommendations can be summarized as follows:

• Aspirin should be given promptly in ACS and continued indefinitely thereafter unless contraindicated.

• DAPT with aspirin and a P2Y12 inhibitor is recommended for 12 months after STEMI when bleeding risk is not high and bleeding complications have not occurred.

• Prasugrel or ticagrelor is preferred to clopidogrel for ACS patients undergoing PCI; clopidogrel remains appropriate when these agents cannot be used.

• Aspirin plus clopidogrel is the standard DAPT regimen after elective PCI for chronic coronary disease.

• Six months is the default DAPT duration after PCI for chronic coronary disease.

• DAPT can be abbreviated to one to three months in patients at high bleeding risk, and may be shortened in selected patients without high ischaemic risk.

• Prolonged intensified treatment should be considered only when ischaemic risk is high and major or life-threatening bleeding risk is not increased.

• Genotype or platelet-function testing is not recommended routinely in chronic coronary disease, although it may guide treatment in selected high-risk PCI patients known to carry a CYP2C19 loss-of-function allele.

• Patients receiving both oral anticoagulation and antiplatelet therapy require reassessment and minimization of combination-treatment duration.

• In stable coronary disease with a chronic indication for full-dose anticoagulation and no recent MI or stent, anticoagulant monotherapy may be appropriate.

Adherence and implementation

The effectiveness of antiplatelet treatment depends on sustained adherence. Secondary prevention frequently fails because patients do not receive or continue evidence-based medications. By one year after MI, only approximately half of patients in high-functioning healthcare systems are taking recommended secondary-prevention medications such as statins; this illustrates the broader implementation problem affecting long-term preventive care.

Barriers include medication cost, treatment complexity, time, health literacy, and limited capacity of patients or caregivers to organize care. Addressing these barriers is part of antiplatelet management. Treatment selection should incorporate patient preferences, anticipated absolute benefit, bleeding concerns, and the feasibility of maintaining the prescribed regimen.

Prognosis and follow-up

Antiplatelet therapy improves long-term prognosis after MI by reducing recurrent infarction, stroke, cardiovascular death, and, after PCI, stent thrombosis. The magnitude of benefit is greatest when the patient’s ischaemic risk is high, but the absolute benefit must be weighed against treatment-related bleeding.

Follow-up should include regular reassessment of:

• recurrent ischaemic events;

• bleeding, including gastrointestinal and intracranial bleeding;

• medication tolerance and adherence;

• the continuing indication for DAPT or combined antiplatelet–anticoagulant therapy;

• changes in renal function or other clinical characteristics relevant to bleeding and ischaemic risk;

• the need for surgery or invasive procedures;

• whether the patient remains eligible for extended intensified therapy.

The duration of intensified antithrombotic treatment should not be regarded as permanently fixed. Periodic reassessment is essential because the balance between recurrent thrombosis and bleeding evolves over time, and randomized evidence beyond the durations tested in the cited studies is unavailable.